Brief: Zydus Lifesciences Says US FDA Grants Priority Review To Zydus Therapeutics' NDA For Saroglitazar To Treat Pbc
BRIEF-Zydus Lifesciences Says US FDA Grants Priority Review To Zydus Therapeutics' NDA For Saroglitazar To Treat Pbc May 28 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
US FDA GRANTS PRIORITY REVIEW TO ZYDUS THERAPEUTICS' NDA FOR SAROGLITAZAR TO TREAT PBC
Source text: ID:nNSE4JhhBV
Further company coverage: ZYDU.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka